Professor Philip Batterham
Professor Philip Batterham is the 2021 Winner of the Tony Ayers Prize for Excellence in Research and Translational Medicine. His research interests include implementing digital tools to prevent mental disorders, reducing risk of suicide, assessing mental health in the population, and reducing the stigma of mental illness.
Dr Michelle Banfield
Dr Michelle Banfield has been awarded the 2019 John James Foundation Tony Ayers Prize for Excellence in Research in Translational Medicine.
Dr Banfield, who is Head of Lived Experience Research at the ANU Centre for Mental Health Research, leads a program that takes a health systems approach to evidence for effective mental health services.
Associate Professor Di Yu received the John James Foundation Tony Ayers Prize for his work in translational medicine in 2018.
Associate Professor Di Yu leads the TIM3 (T-Cell Immune Mechanism, Monitoring and Modulation) at The John Curtin School of Medical Research. His group investigates the molecular mechanisms used by T-cells to regulate and balance the immune response, to design new strategies for immunotherapies to treat inflammation, autoimmune diseases, infections and cancer.
Professor Robyn Lucas
Professor Robyn Lucas has been awarded the 2016 John James Foundation Tony Ayers Prize for Excellence in Translational Medicine.
Professor Lucas, Director of the National Centre for Epidemiology and Population Health, was recognised for her work investigating links between sun exposure, Vitamin D and multiple sclerosis.
Dr Anselm Enders was presented with the 2015 John James Foundation Tony Ayers Prize for Excellence in Research in Translational Medicine. Dr Enders presented a public lecture on his work, which is designed to translate findings from mouse models in order to better understand the pathogenesis of human immunodeficiencies.
Dr Anneke Blackburn, an expert in the use of a cheap, non-toxic drug, known as DCA, as a cancer therapy. Dr Blackburn’s pre-clinical studies on the effect of DCA in breast cancer have been extended to include work on colon cancer, prostate cancer, sarcomas and multiple myeloma and will result in the first clinical trial of the drug with multiple myeloma patients in Australia at The Canberra Hospital late in 2014.
Dr Blackburn’s research is investigating how metabolism controls the ability of cancer cells to grow, spread and resist cell death. The results will be used to target cancer cells with DCA, with the potential to offer additional treatment options for people with recurrent cancer.